Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Nexstim Plc

Market Cap 80.75M 93.49M 74.41M 69.65M 131M 8.89B 133M 879M 343M 4.33B 351M 343M 14.98B P/E Ratio 2026 *
83.3x
P/E Ratio 2027 * 37x
Enterprise Value 78.65M 91.06M 72.47M 67.84M 127M 8.66B 129M 856M 334M 4.21B 342M 334M 14.59B EV / Sales 2026 *
6.19x
EV / Sales 2027 * 4.79x
Free-Float
58.2%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 49 11/02/2020
Director of Finance/CFO 40 11/02/2020
Chief Tech/Sci/R&D Officer 65 01/01/2008
Director TitleAgeSince
Director/Board Member 64 11/11/2019
Chairman 63 11/11/2019
Director/Board Member 55 01/05/2021
Change 5-day change 1-year change 3-year change Capi.($)
-1.14%-0.86% - - 93.49M
+1.52%+1.19%+17.31%-11.19% 174B
+1.32%-0.47%-19.72%+26.93% 146B
+0.70%-1.02%-9.67%-25.40% 127B
+0.13%-3.49%-53.69%-12.93% 69.72B
+0.65%-0.16%+14.56%-6.11% 49.01B
+0.95%+1.72%-24.07%-33.43% 44.74B
+1.03%-1.12%+10.24%+8.23% 36.67B
+0.86%-1.33%+3.08%+33.73% 34.91B
+0.18%+1.06%-10.30%-17.38% 29.65B
Average +0.65%-1.85%-8.03%-4.17% 79.13B
Weighted average by Cap. +1.01%-1.87%-7.04%-4.22%

Financials

2026 *2027 *
Net sales 12.7M 14.7M 11.7M 10.95M 20.53M 1.4B 20.85M 138M 53.88M 680M 55.18M 54.01M 2.36B 16.1M 18.64M 14.84M 13.89M 26.03M 1.77B 26.43M 175M 68.3M 862M 69.96M 68.47M 2.99B
Net income 1M 1.16M 922K 863K 1.62M 110M 1.64M 10.88M 4.24M 53.57M 4.35M 4.25M 185M 2.2M 2.55M 2.03M 1.9M 3.56M 242M 3.61M 23.94M 9.33M 118M 9.56M 9.36M 408M
Net Debt -2.1M -2.43M -1.94M -1.81M -3.39M -231M -3.45M -22.85M -8.91M -112M -9.13M -8.93M -389M -3.7M -4.28M -3.41M -3.19M -5.98M -407M -6.07M -40.26M -15.7M -198M -16.08M -15.74M -686M
Logo Nexstim Plc
Nexstim Oyj is a Finland-based medical technology company. It is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!